MedTrace Logo

Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced Hematological Malignancies (R-PLQ)

NCT03806712 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2019-07-25

No results posted yet for this study

Summary

Limited data is available for end of life care in hematologic malignancies, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting and there's a lack of recommendation. The final decision is take by the clinician and his patient, but no study exist in representation of the two parts. We provide a qualitative study to understand what this decision is made of.

Conditions

  • Platelet Transfusion
  • Hematological Malignancy
  • Palliative Care

Interventions

OTHER

multi method questionary (developped by De Rosa, in 1995 and 2014)

questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-06-01
Completion
2019-07-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03806712 on ClinicalTrials.gov